Skip to main content

Advertisement

SpringerLink
Log in

Dose modifications of anti-TNF drugs in rheumatoid arthritis patients under real-world settings: a systematic review

  • Original Article - Observational Research
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Anti-TNF dose modifications in rheumatoid arthritis have implications on healthcare resource utilization. The objective was to systematically review the dose modifications, both escalations and reductions, of currently available anti-TNF drugs (adalimumab, certolizumab, etanercept, golimumab and infliximab) in the real-world setting. We performed a systematic literature search of MEDLINE, ISI Web of Science, EMBASE, Indice Médico Español databases and American College of Rheumatology and European League Against Rheumatism annual congresses databases. PRISMA and MOOSE guidelines were followed. Only observational studies were included. Clinical trials were excluded since they do not reflect routine clinical practice. Dose escalations and reductions of the anti-TNF drug and their magnitude were collected. Thirty-four studies fulfill the inclusion criteria. Etanercept was associated with the lower percentage of patients under dose escalation (4.5 %; range 0–22 %), both in naïve (4.9 %) and non-naïve patients (1.3 %). Adalimumab and infliximab were associated with significantly higher percentages. Dose modification magnitude in those patients compared to basal dose was significantly different between treatments; 7.1 % (95 % CI 6.3–7.9 %) in etanercept, 30.4 % (95 % CI 28.3–32.5 %) in adalimumab and 21 % (95 % CI 20.3–21.7 %) in infliximab. Adalimumab and infliximab were associated with a higher risk of dose escalation relative to etanercept. There were no significant differences in the dose reduction percentages for the whole group of patients between treatments. In rheumatoid arthritis, etanercept is associated with a significantly lower percentage of dose-escalated patients and a lower magnitude of dose modification. Significant differences in the dose reduction between anti-TNF drugs evaluated were not observed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Aaltonen K, Virkki LM, Malmivaara A et al (2012) Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. Plos One. 7(1):e30275

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. Alonso-Ruiz A, Pijoan JI, Ansuategui E, et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord [Internet]. 2008; 9: 52; doi:10.1186/1471-2474-9-52 (cited 2014 Dec 20)

  3. Weins A, Venson R, Correr CJ et al (2010) Meta-analysis of the efficacy and safety of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy 30(4):339–353

    Article  Google Scholar 

  4. Felson DT, Smolen JS, Wells G et al (2011) American college of rheumatology/European league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 70:404–413

    Article  PubMed  Google Scholar 

  5. Anderson J, Caplan L, Yazdany J et al (2012) Rheumatoid arthritis disease activity measures: American college of rheumatology recommendations for use in clinical practice. Arthritis Care Res 64(5):640–647

    Article  Google Scholar 

  6. Tornero J, Sanmartí R, Rodriguez V et al (2010) Actualización del documento de consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en la artritis reumatoide. Reumatología Clin. 6(1):23–36

    Article  Google Scholar 

  7. Vincent FB, Morand EF, Murphy K et al (2013) Antidrug antibodies (ADAb) to tumor necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 72(2):165–178

    Article  CAS  PubMed  Google Scholar 

  8. Garces S, Demengeot J, Benito-García E (2013) The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 72(12):1947–1955

    Article  CAS  PubMed  Google Scholar 

  9. Nair K, Tang B, Van Den Bos J et al (2009) Categorization of infliximab dose changes and healthcare utilization and expenditures for patients with rheumatoid arthritis in commercially insured and medicare populations. Curr Med Res Opin 25(2):303–314

    Article  CAS  PubMed  Google Scholar 

  10. Harrison D, Huang X, Globe D (2010) Dosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritis. Am J Health Syst Pharm. 67(15):1281–1287

    Article  CAS  PubMed  Google Scholar 

  11. Ariza-Ariza R, Navarro-Sarabia F, Hernández-Cruz B et al (2007) Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review. Rheumatology. 46(3):529–532

    Article  CAS  PubMed  Google Scholar 

  12. Kievit W, Fransen J, Oerlemans A et al (2007) The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomized controlled trials and clinical practice. Ann Rheum Dis 66(11):1473–1478

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Liberati A, Altman D, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62(10):e1–e34

    Article  PubMed  Google Scholar 

  14. Stroup D, Berlin J, Morton S et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 283(15):2008–2012

    Article  CAS  PubMed  Google Scholar 

  15. Higgins P, Green S. Cochrane Handbook for systematic reviews of interventions version 5.1.0, the cochrane collaboration, 2011. Available: http://handbook.cochrane.org/ (cited: 2014 Dec 22)

  16. Higgins J, Thompson S, Deeks J et al (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560

    Article  PubMed Central  PubMed  Google Scholar 

  17. Berger A, Edelsberg J, Li T et al (2005) Dose intensification with infliximab in patients with rheumatoid arthritis. Rheumatology 39(12):2021–2025

    CAS  Google Scholar 

  18. Ollendorf D, Klingman D, Hazard E et al (2009) Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population. Clin Ther 31(4):825–835

    Article  CAS  PubMed  Google Scholar 

  19. Ollendorf D, Massarotti E, Birbara C et al (2005) Frequency, predictors, and economic impact of upward dose adjustment of infliximab in managed care patients with rheumatoid arthritis. J Manag Care Pharm. 11(5):383–393

    PubMed  Google Scholar 

  20. Vollenhoven R, Brannemark S, Klareskog L (2004) Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect. Ann Rheum Dis 63(4):426–430

    Article  PubMed Central  PubMed  Google Scholar 

  21. Escudero-Vilaplana V, Ramírez-Herraiz E, Trovato-López N et al (2012) Influence on effectiveness of early treatment with anti-TNF therapy in rheumatoid arthritis. J Pharm Pharmaceut Sci. 15(2):355–360

    CAS  Google Scholar 

  22. Kievit W, Adang E, Fransen J et al (2008) The effectiveness and medication costs of three anti-tumour necrosis factor α agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann Rheum Dis 67(9):1229–1234

    Article  CAS  PubMed  Google Scholar 

  23. Favalli EG, Marchesoni A, Colombo GL, Sinigaglia L (2008) Pattern of use, economic burden and vial optimization of infliximab for rheumatoid arthritis in Italy. Clin Exp Rheumatol 26(1):45–51

    CAS  PubMed  Google Scholar 

  24. Kristensen LE, Geborek P, Saxne T (2009) Dose escalation of infliximab therapy in arthritis patients is related to diagnosis and concomitant methotrexate treatment: observational results from the south Swedish arthritis treatment group register. Rheumatology 48(3):243–245

    Article  CAS  PubMed  Google Scholar 

  25. Huang X, Gu NY, Fox KM et al (2010) Comparison of methods for measuring dose escalation of the subcutaneous TNF antagonists for rheumatoid arthritis patients treated in routine clinical practice. Curr Med Res Opin 26(7):1637–1645

    Article  CAS  PubMed  Google Scholar 

  26. Bolge SC, Carter CT, Mueller CS et al (2012) Comparative multidatabase analysis of dosing patterns and infusion intervals for the first 12 infliximab infusions in patients with rheumatoid arthritis. Clin Ther 34(12):2286–2292

    Article  CAS  PubMed  Google Scholar 

  27. Moots RJ, Haraoui B, Matucci-Cerinic M et al (2011) Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice. Clin Exp Rheumatol 29(1):26–34

    PubMed  Google Scholar 

  28. Scheinberg M, Goldenberg Feldman D P et al (2008) Retrospective study evaluating dose standards for infliximab in patients with rheumatoid arthritis at Hospital Israelita Albert Einstein, São Paulo, Brazil. Clin Rheumatol. 27(8):1049–1052

    Article  PubMed  Google Scholar 

  29. Ogale S, Hitraya E, Henk H J. Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord. [Internet]. 2011; 12: 204; doi: 10.1186/1471-2474-12-204(cited: 2014 Dec 15)

  30. Punzi L, Matucci-Cerinic M, Cantini F et al (2011) Treatment patterns of anti-TNF agents in Italy: an observational study. Reumatismo. 63(1):18–28

    Article  CAS  PubMed  Google Scholar 

  31. Fisher MD, Watson C, Fox KM et al (2013) Dosing patterns of three tumor necrosis factor blockers among patients with rheumatoid arthritis in a large United States managed care population. Curr Med Res Opin 29(5):561–568

    Article  CAS  PubMed  Google Scholar 

  32. Ramírez-Herráiz E, Escudero-Vilaplana V, Alañón-Plaza E et al (2013) Efficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: dosing patterns and effectiveness in daily clinical practice. Clin Exp Rheumatol 31(4):559–565

    PubMed  Google Scholar 

  33. Schabert VF, Bruce B, Ferrufino CF et al (2012) Disability outcomes and dose escalation with etanercept, adalimumab, and infliximab in rheumatoid arthritis patients: a US-based retrospective comparative effectiveness study. Curr Med Res Opin 28(4):569–580

    Article  CAS  PubMed  Google Scholar 

  34. Yazici Y, Krasnokutsky S, Barnes JP et al (2013) Changing patterns of tumor necrosis factor inhibitor use in 9074 patients with rheumatoid arthritis. J Rheumatol 36(5):907–913

    Article  Google Scholar 

  35. Blume SW, Fox KM, Joseph G et al (2013) Tumor necrosis factor-blocker dose escalation in rheumatoid arthritis patients in a pharmacy benefit management setting. Adv Ther. 30(5):517–527

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  36. Inciarte-Mundo J, Hernández MV, Rosario V et al (2014) Reducción de dosis de terapias biológicas en enfermedades reumáticas: análisis descriptivo de 153 pacientes en condiciones de práctica clínica. Reumatol Clin. 10(1):10–16

    Article  PubMed  Google Scholar 

  37. Bonafede MK, Gandra SR, Fox KM et al (2012) Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation. J Med Econ. 15(4):1–9

    Article  Google Scholar 

  38. Blom M, Kievit W, Kuper HH et al (2010) Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice. Arthritis Care Res (Hoboken). 62(9):1335–1341

    Article  CAS  PubMed  Google Scholar 

  39. Wu E, Chen L, Birnbaum H et al (2008) Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis. Curr Med Res Opin 24(8):2229–2240

    Article  CAS  PubMed  Google Scholar 

  40. Joyce A, Gandra S, Fox K et al (2014) National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naïve rheumatoid arthritis patients in US health plans. J Med Econ. 17(1):1–10

    Article  PubMed  Google Scholar 

  41. Abarca J, Malone D, Armstrong E et al (2004) Longitudinal analysis of the use of etanercept versus infliximab determined from medical chart audit. J Manag Care Pharm. 10(6):538–542

    PubMed  Google Scholar 

  42. Etemad L, Yu B, Wanke A (2005) Dose adjustment over time of etanercept and infliximab in patients with rheumatoid arthritis. Manag Care Interface. 18(4):21–27

    PubMed  Google Scholar 

  43. George D, Kadlubek P, Batra D, et al. Infliximab dose and charge escalation patterns in managed care. Manag Care Interface. 2004; Suppl A:5–8

  44. Gilbert T Jr, Smith D, Ollendorf D (2004) Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord. 5(1):36

    Article  PubMed Central  PubMed  Google Scholar 

  45. Harley CR, Frytak JR, Tandon N (2003) Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care. 9(suppl.6):s136–s143

    PubMed  Google Scholar 

  46. Stern R, Wolfe F (2004) Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis. J Rheumatol 31(8):1538–1545

    CAS  PubMed  Google Scholar 

  47. Agarwal SK, Maier AL, Chibnik LB et al (2005) Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical center. Arthritis Rheum 53(6):872–878

    Article  CAS  PubMed  Google Scholar 

  48. Van Vollenhoven RF, Klareskog L (2007) Infliximab dosage and infusión frequency in clinical practice: experience in the Stockholm biologics registry STURE. Scand J Rheumatol 36(6):418–423

    Article  PubMed  Google Scholar 

  49. Daniel G, McNeely B, Huang X, et al. Dose patterns and health plan costs among RA patients treated with tumor necrosis factor antagonists. [abstract]. American College of Rheumatology. Annual Scientific Meeting 2008. Available: https://acr.confex.com/acr/2008/webprogram/Paper3442.html

  50. Khanna D, Cyhaniuk A, Bedenbaugh A (2011) Use of TNF-inhibitors in the US: utilisation patterns and dose escalation from a representative US rheumatoid arthritis (RA) population. [abstract]. Ann Rheum Dis. 70(suppl.3):97

    Google Scholar 

  51. Tang B, Greenburg J, Reed G et al (2009) Analysis of infliximab dose and interval patterns in patients with rheumatoid arthritis in the consortium of rheumatology researchers of North America (CORRONA) registry. [abstract]. Ann Rheum Dis 68(Suppl. 3):231

    Google Scholar 

  52. Engel-Nitz N, Huang X, Globe D et al (2007) Dosing patterns and costs of adalimumab, etanercept, and infliximab among patients with rheumatoid arthritis. [abstract]. Ann Rheum Dis. 66(suppl II):260

    Google Scholar 

  53. Zhang J, Xie F, Delzell E, et al. Persistent use of biologic therapies at lower than recommended dosing among rheumatoid arthritis patients enrolled in the US medicare program. [abstract]. American College of Rheumatology. Annual Scientific Meeting 2013. Available: https://ww2.rheumatology.org/apps/MyAnnualMeeting/Abstract/34866

  54. Hanna B, Shah A. Drug survival and long-term dose comparison of etanercept and infliximab in rheumatoid arthritis patients. [abstract]. American College of Rheumatology. Annual Scientific Meeting 2011. Available: https://acr.confex.com/acr/2011/webprogram/Paper20448.html

  55. Darkow T, Chastek B, Rosenblatt L et al (2011) Dose escalation among rheumatoid arthritis patients treated with infliximab or abatacept: comparison in claims Data. [abstract]. Arthritis Rheum. 63(suppl.10):1221

    Google Scholar 

  56. Tang B, Rahman R, Waters HC et al (2008) Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis. Clin Ther 30(7):1375–1384

    Article  CAS  PubMed  Google Scholar 

  57. Hetland M, Christensen U, Tarp U et al (2010) Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab results from eight years of surveillance of clinical practice in the nationwide Danish DANIBIO registry. Arthritis Rheum 62(1):22–32

    Article  CAS  PubMed  Google Scholar 

  58. Marchesoni A, Zaccara E, Gorla R et al (2009) TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci 1173:837–846

    Article  CAS  PubMed  Google Scholar 

  59. Ward M (2010) Medicare reimbursement and the use of biologic agents: incentives, access, the public good, and optimal care. Arthritis Care Res (Hoboken) 62(3):293–295

    Article  Google Scholar 

  60. DeWitt E, Glick H, Albert D et al (2006) Medicare coverage of tumor necrosis factor α inhibitors as an influence on physicians’ prescribing behavior. Arch Intern Med. 166(13):57–63

    Article  PubMed  Google Scholar 

  61. Wolbink GJ, Vis M, Lems W et al (2006) Development of antiinfliximab antibodies and relationship to clinical response in patient with rheumatoid arthritis. Arthritis Rheum 54(3):711–715

    Article  PubMed  Google Scholar 

  62. Bartelds GM, Wijbrandts CA, Nurmohamed MT et al (2007) Clinical reponse to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 66(7):921–926

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  63. Pascual-Salcedo D, Plasencia C, Ramiro S et al (2011) Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford) 50(8):1445–1452

    Article  CAS  Google Scholar 

  64. Korswagen LA, Bartelds GM, Krieckaert CL et al (2011) Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study. Arthritis Rheum 63(4):877–883

    Article  CAS  PubMed  Google Scholar 

  65. Singh J, Christensen R, Wells G et al (2009) A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane review. CMAJ 181(11):787–796

    Article  PubMed Central  PubMed  Google Scholar 

  66. Curtis J, Jain A, Askling J et al (2010) A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum 40(1):2–14

    Article  PubMed Central  PubMed  Google Scholar 

  67. Wolfe F, Michaud K (2005) Towards an epidemiology of rheumatoid arthritis outcome with respect to treatment: randomized controlled trials overestimate treatment response and effectiveness. Rheumatology 44(suppl.4):iv8–iv22

    Google Scholar 

  68. Schabert V, Gandra C, Goodman S et al (2012) Annual costs of tumor necrosis factor inhibitors using real-world data in commercially insured population in the United States. J Med Econ. 15(2):264–275

    Article  PubMed  Google Scholar 

  69. Sanderson S, Tatt I, Higgins J et al (2007) Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. Int J Epidemiol 36(3):666–676

    Article  PubMed  Google Scholar 

  70. Dreyer N, Velentgas P, Westrich K et al (2014) The GRACE checklist for rating the quality of observational studies of comparative effectiveness: a tale of hope and caution. J Manag Care Pharm 20(3):301–308

    Google Scholar 

  71. Zandvliet M, Bezooijen J, Bos M et al (2013) Monitoring antigen-specific biologics: current knowledge and future prospects. Ther Drug Monit 35(5):588–594

    CAS  PubMed  Google Scholar 

  72. Azevedo V, Galli N, Kleinfelder A, et al. Etanercept biosimilar. Rheumatol Int [Internet]. 2014. doi:10.1007/s00296-014-3080-5 (cited: 2014 Dec 20)

Download references

Conflict of interest

Authors received an honorarium from Pfizer in connection with the development of the manuscript.

Author information

Authors and Affiliations

  1. Pharmacy Service, Clinic University Hospital, Avda Blasco Ibáñez, 17, 46010, Valencia, Spain

    Rafael Ferriols-Lisart & Francisco Ferriols-Lisart

Authors
  1. Rafael Ferriols-Lisart
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francisco Ferriols-Lisart
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rafael Ferriols-Lisart.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ferriols-Lisart, R., Ferriols-Lisart, F. Dose modifications of anti-TNF drugs in rheumatoid arthritis patients under real-world settings: a systematic review. Rheumatol Int 35, 1193–1210 (2015). https://doi.org/10.1007/s00296-015-3222-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-015-3222-4

Keywords

Search

Navigation